Share
Ecouter

Salient facts


  •  Four articles produced by the team have gained particular interest:

                      ♦  Dubois A et al. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum. Am J Respir Crit Care Med. 2013 188:703-9. This article was discussed in 2 separate editorials (one appearing in 2013, and the other in 2014) in this same leading journal.
                                 - Faster, Higher, Stronger. Am J Respir Crit Care Med. 188:6, 634-635 (2013)

- Update in Cystic Fibrosis 2013. Am J Respir Crit Care Med. 189:10, 1181-1186 (2014)


                      ♦  Guillon A et al. Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence. Eur. Respir. J. 2015 46:771-82. This article was discussed as a scientific brief in the magazine “Science & Santé” published by Inserm (n°27, Sept.-Oct. 2015).

                      ♦  Blanc F et al. Targeting host calpain proteases decreases influenza A virus infection. Am J Physiol Lung Cell Mol Physiol. 2016 310:L689-99. This article was included in an Inserm press release (http://presse.inserm.fr/en/calpains-key-cellular-enzymes-for-fighting-influenza/22434/) and received media coverage in numerous specialised French journals (Quotidien du médecin, Académie nationale de pharmacie, Moniteur des pharmacies, Science & Avenir,…), in the mainstream press (Ouest-France, Le Parisien, La Dépêche, Le point,…) and on a regional programme televised by France 3.

                      ♦  Henry et al. In vitro and in vivo evidence for an inflammatory role of the calcium channel TRPV4 in lung epithelium: Potential involvement in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016 311:L664-75. This article was distinguished by this journal in its APSselect section (“APSselect is a collection of the very best original research papers published by the American Physiological Society” http://apsselect.physiology.org)

 

  • Acquisition of 3 European patents:

·              EP N°14306943.3 filed in December 2014 “METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE”

·                     EP N°15306102.3 filed in July 2015 "INSERTION TUBE FOR FLEXIBLE BRONCHOSCOPE"

·                     EP N° 15306598.2 filed on 9 October 2015 “METHODS FOR INHIBITING OR REDUCING BACTERIAL BIOFILMS” )
 

  • Organisation of 3 international conferences in Tours:

“CPC-Inserm Lung summer school” (2013); “Studium Conference on Chronic inflammatory lung diseases" (2013); “International Conference on Cystic fibrosis: contribution of animal models to therapeutic development” (2015).


“12th World Congress on Inflammation, IAIS meeting, Boston – USA (2015). Symposium GREMI : "The Neutrophil: An old dog with new trick" ”; “1st Challenge in inflammation meeting: Regulatory checkpoints and resolution. Florence, Italy (2016). Jointly organised with Labex Inflamex, SIF and GREMI”.

  •  Acquisition in late 2015 of a European funding for the “Joint Programming Initiative on Antimicrobial Resistance” (theme: Repurposing disused antibiotics with immune modulators as antimicrobial strategy for respiratory tract infections; coordinator: Dr. JC Sirard, CIIL, Lille).

 

  • Prof. PF Dequin, head of the critical care department at Tours University Hospital and member of team 1, obtained a “national PHRC” (hospital clinical research)” grant (theme: Etude de l'Influence des corticosteroïdes à doses faibles sur l'évolution des pneumopathies aiguës communautaires graves / Study of the effects of low-dose corticosteroid therapy on the evolution of severe community-acquired acute lung diseases).

 

  • A. Guillon was awarded a highly competitive “Inserm research fellowship” (“contrat d’interface”) funding for 2 years to complete his PhD thesis (2012-2014 period; topic: altération de la réponse immunitaire dépendante de l’interleukine-22 lors de pathologies respiratoires / alternations in interleukin-22 receptor-dependent immune response in respiratory diseases).

 

  • Y. Jouan also received this competitive “Inserm research fellowship” funding for 2 years (from November 2016) to complete a scientific thesis (topic: De la pneumonie au Syndrome de Détresse Respiratoire Aiguë (SDRA) : Rôle des populations cellulaires productrices d’IL-17 et d’IL-22 / From pneumonia to Acute Respiratory Distress Syndrome (ARDS): The role of IL-17 and IL-22-producing cell populations).

 

  • Hosting of an American researcher (Prof. Reuben Ramphal, University of Florida) by the team for 18 months (May 2013 – November 2014). Prof. Ramphal participated in developing programmes focusing on the virulence of P. aeruginosa.

 

  • Arrival in July 2016 of a new researcher (Dr. Christophe Paget, CR1 Inserm, whose expertise is in lung mucosa immunity)